Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(55)
•••
Comment by frohlir944on Mar 03, 2018 6:23pm
128 Views
Post# 27656954

RE:RE:RE:RE:RE:RE:RE:RE:almost like

RE:RE:RE:RE:RE:RE:RE:RE:almost likeMoronic behavior by yourself and a few others has completely drowned out any positive posts.  You are completely responsible for the current stock price. ( the only positive is that a few of us have been able to add cheap shares as a result of your foolishness).

Because the current phase of development has to be done in secrecy ( due to requirements dictated by pharma partners) there has been little overt news, but being able to read between the lines in the MD&A, the moving of office to the US, development of a US website, all the clues are pointing to a US listing, and Nasdaq is the only obvious choice.  

When end the time is right and all the puzzle pieces are aligned, you better believe that there will be a strategic push to get this listed, which means lots off news in quick succession.  

In conclusion when we have a huge move in stock price, it will be in spite of all your foolishness.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities